Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy | Aplastic Anemia & MDS International Foundation Return to top.
  1. Education
  2. Research Articles
  3. Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy

Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy

Journal Title: 
Leukemia & Lymphoma
Primary Author: 
Lee S
Author(s): 
Lee S, Desai P, Edirisinghe B, Pianello S, Curcio T, Samuel M, Ritchie EK, Roboz GJ
Original Publication Date: 
Saturday, October 10, 2020
Full Article on PubMed: 
https://www.ncbi.nlm.nih.gov/pubmed/33043735/
Bone Marrow Disease(s): 
  • myelodysplastic syndromes (MDS)
Share with addtoany.com.